The next Buzz in Medical Aesthetics & The Future of Skin Rejuvenation
The world’s only medical, solid-state laser producing both 589nm (Yellow Laser) and 1319nm (Infrared) wavelengths.
The combination of high powered yellow and infrared laser energy to improve skin tone, texture and overall dermal health by targeting the vascular components of melasma, dyschromia, sun damage and unwanted pigment while simultaneously reducing wrinkles, limiting oil production and shrinking pore size.
Combining pure yellow and high-powered infrared laser energy to eliminate rosacea, acne, acne scars and undesired vascular abnormalities such as telangiectasia, hemangiomas and venous lakes, restoring the skin to a more youthful and healthy state.
ADVATX HAS OVER 25 FDA/CE CLEARED INDICATIONS
Bringing world-class laser revolution to dermatology and aesthetic medicine
Results that Speak !
Melasma, Hyperpigmentation, Active Acne, Skin Texture
Before / After
VARIETY OF TREATMENTS
SKIN REJUVENATION
Combining 589 and 1319nm wavelengths initiates an inflammatory response by targeting superficial vasculature while at the same time causing thermal injury to the papillary dermis, intitiating the body's natural wound healing response, stimulating fibroblast activity and the formation of Type 1 and 3 collagen, resulting in visible improvement to tone and texture.
ACNE
By targeting the p.acne bacteria itself, the vascular component to active lesions and the underlying oil production by the sebaceous glands, the ADVATx employs a multi-pronged approach to reducing active acne.
VASCULAR
The ideal ratio of oxyhemoglobin to melanin absorption of 589nm, coupled with the PulSync delivery system, provides for the ability to safely and effectively treat a broad range of vascular abnormalities without patient downtime.
MELASMA
By addressing the underlying vascular components with 589nm and the sebaceous gland component with 1319nm, melasma is targeted on multiple fronts. The absorption characteristics and delivery mechanism allow treatment with a low risk of PIH.